The two companies announced positive topline results for the drug in pretreated EGFR exon 20 insertion mutation NSCLC, a market that Takeda vacated in 2023.
Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer (NSCLC) patients whose disease harbors epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The companies announced topline results on 28 January of the Phase IIb portion of the trial for zipalertinib, also known...
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
